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Italian-THAlassemia-Cosy-&-Outcomes-Assessment (ITHACA)
was a naturalistic multicentre study conducted to evaluate costs,
quality of life, compliance and treatment satisfaction in MT
patients undergoing ICT. In total 126 MT patients >12 years old
completed a 28-item satisfaction instrument consisting of 4
domains (perceived effectiveness, burden, side effects, accep-
tance. Response continuum ranged from 1 (very dissatisﬁed) to
5 (very satisﬁed). RESULTS: The median age was 29.4 years
(12.3–48.5), with an equal proportion of males and females. At
enrolement, 48.0% were treated with Deferoxamine, 33.6%
with Deferiprone and 18.4% with combination treatment.
86.5% of patients had at least one MT-related complication and
13.5% changed treatment regimens at least once during the
observational period (11.6 median months). Mean satisfaction
scores for “acceptance”, “side effects”, “burden” and “perceived
effectiveness” were 3.37, 3.57, 3.87 and 4.29 respectively. Simple
linear regression analysis showed that satisfaction with “accep-
tance” (R2 = 11%), “burden” (R2 = 13%) and “side effects”
(R2 = 12.3%) are signiﬁcantly and positively associated with the
adherence item “never thinking about stopping medication” 
(p < 0.0001 in both cases). CONCLUSIONS: The level of satis-
faction with “burden”, “acceptance” and “side effects” in MT
patients undergoing ICT can help to predict patient adherence.
Strategies able to improve satisfaction with ICT are expected to
increase patients’ adherence, with potential signiﬁcant conse-
quences on treatment effectiveness.
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OBJECTIVES: New anticoagulant drugs, alternative to vitamin
K antagonist (VKA) are currently under clinical evaluation.
Patients’ preferences should be considered in the development of
new therapeutic strategies. Objective of this study was to elicit
patients’ preferences on different treatment options. METHODS:
A discrete-choice-exercise (2 different scenarios in 9 pair-wise
comparisons) was applied to consecutive patients of all ages on
stable OAT or during their OAT starting-visit. The following
attributes were considered to be important after interviewing 20
patients and 6 physicians: route and number of administrations,
monitoring frequency, minor bleedings (few vs. no), treatment
out-of-pocket payment (€0 vs. €15 vs. €75/month), drugs/food
interactions and dose-adjustment (required vs. not-required). The
Possible relationship between sociodemographic and/or clinical
characteristics of the respondents and their preferences were eval-
uated. RESULTS: The questionnaire was completed by 237
patients (55%male; mean-age = 63/ds = 14; 41%on-stable-OAT).
A signiﬁcant monetary discrimination was reached for all attrib-
utes, except “interactions” and “dose adjustment”. The condi-
tional-probit-model demonstrated that patients are willing-to-pay
(WTP) per month: €79 for once-daily administration-tablets vs
one subcutaneous weekly-injection; €41 for once-daily adminis-
tration-tablets vs. twice-daily administration-tablets; €21 for
once-monthly vs. twice-monthly; €18 for each 6 month vs. once-
monthly visits; €23 for a drug without bleeding-risk. The model
showed important differences between stable and starting OAT
patients: the WTP for less frequent monitoring and no interac-
tions is greater for patients in stable-OAT; the WTP to avoid bleed-
ings is greater for starting patients. Also the employment status
matters: employed patients are more willing to pay for a treat-
ment with less frequent monitoring. CONCLUSIONS: To our
knowledge, this study is the ﬁrst to elicit preferences from patients
in OAT. The importance of this study is the achievement of
patient’s preferences in a simply and well accepted method to
allow planning optimal health care.
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OBJECTIVES: To estimate impact of dutasteride reimbursement
on budget from the perspective of National Health Fund (NHF)
in Poland. METHODS: Decision-analytic model was developed
to assess budget impact of dutasteride. Costs and resource use
are from published literature and NHF catalogue of procedures.
Costs of drugs, surgical intervention and prostate cancer treat-
ment were taken into account. Clinical data, including compli-
cations and prostate cancer rates, were obtained from the clinical
effectiveness analyses of dutasteride. Budget impact analysis was
performed in four different scenarios with regard to reimburse-
ment reference price and rates (Scenario 1: 50% reimbursement
rate, reference price = reference price for Penester; Scenario 2:
50% reimbursement rate, reference price = Avodart price; Sce-
nario 3: 70% reimbursement rate, reference price = reference
price for Penester; Scenario 4: 70% reimbursement rate, refer-
ence price = Avodart price). RESULTS: In case of Avodart (dutas-
teride) reimbursement, NHF would save: 65,888–562,612 PLN
in year 1, 197,664–1,687,836 PLN in year 2, 300,477–
2,625,523 PLN in year 3 and 376,229–3,212,590 PLN in year
4 and later, depending on assumed reimbursement reference price
and rate. CONCLUSIONS: Reimbursement of dutasteride
would result is savings from the perspective of the National
Health Fund in Poland.
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OBJECTIVE: The choice is between two types of hormones used
for follicle stimulation in IVF treatment—recom-binant FSH
(rFSH) and the urine-derived menotrophin. A literature review
by NICE in the UK carried out in 2004 documented that the two
types of hormones were equally effective and safe consequently
it was recommended to use the cheaper menotrophin. Based on
ﬁndings by the European and Israeli Study Group (EIGS), the
objective was to analyse the health economic consequences of
this choice between the two types of hormone in IVF treatment
in Denmark. METHODS: Based on the EISG study a prospec-
tive cost-effectiveness analysis, which compared menotrophin
(Menopur®) and rFSH (Gonal-F®), was carried out. The analy-
sis had a health care sector perspective with the inclusion of costs
of hormone stimulation, visits, ultrasound, IVF, ICSI and inpa-
tient stay at the hospital. Danish unit costs (2005) were applied.
Differences in costs were compared with differences in effects to
